QHSLab USAQ

QHSLab, Inc. is a digital health company focused on enabling independent primary care practices to identify, document, and manage underdiagnosed and undertreated behavioral health conditions through workflow-integrated digital screening and non-face-to-face follow-up care. The company’s platform supports population-based screening, patient education, and follow-up care management activities that occur outside of traditional in-office encounters. In addition to its digital health platform, QHSLab, Inc. offers an allergy diagnostics and treatment service line under the AllergiEnd® brand, designed to operate synergistically with the digital platform by enabling primary care practices to identify and manage allergic disease within the primary care setting.

QHSLab, Inc. generates revenue primarily through recurring per-patient, per-month fees paid by participating medical practices for access to and use of its digital platform and associated services. These fees are structured as flat amounts tied to platform access, digital care workflows, and support services. The company does not bill patients or payers directly; instead, participating practices are responsible for billing applicable payers for clinical services rendered using the platform, including digital assessments, asynchronous interactions, and care management services, subject to payer coverage, documentation, and compliance requirements. Revenue varies based on patient participation, service utilization, and the number of active patients enrolled by each practice.

QHSLab, Inc. operates through the following segments: QHSLab Digital Platform and AllergiEnd® Allergy Diagnostics and Treatment.

• QHSLab Digital Platform: This segment provides a modular and extensible digital health platform designed to function as an extension of a medical practice’s existing clinical workflow. Core capabilities include digital health assessments administered prior to or outside of office visits, adaptive assessment logic that adjusts based on patient responses, identification of clinical risk factors and patient-reported interest in receiving care, imminent risk alerts with patient and provider next-step instructions, automated generation of patient-facing and provider-facing reports, delivery of provider reports into the practice’s electronic health record, and ongoing digital follow-up, education, and periodic patient check-ins. The platform supports reimbursable clinical activities such as digital assessments, asynchronous interactions, and care management services, enabling practices to capture, stratify, escalate, document, dashboard, and reimburse across primary care populations.
• AllergiEnd® Allergy Diagnostics and Treatment: This segment offers an allergy diagnostics and treatment service line designed to enable primary care practices to identify and manage allergic disease within the primary care setting. The AllergiEnd® product line consists primarily of FDA-cleared, disposable, single-use allergy skin test applicators and matching test trays designed for office-based use, enabling testing for a broad range of common allergens. As part of its service offering, QHSLab, Inc. provides training and operational support related to digital allergy screening using the QHSLab platform, in-office allergy skin testing procedures, interpretation of test results, and integration of allergy findings into patient care plans, while allergen immunotherapy preparations are provided by third-party compounding pharmacies pursuant to prescriptions issued by treating physicians.

QHSLab, Inc. operates in the digital health and allergy diagnostics markets, competing with point-solution digital health vendors, behavioral health screening and care management platforms, chronic care management software providers, EHR-embedded tools and third-party add-ons, and allergy diagnostic device manufacturers and specialty-focused providers. Many competitors possess greater financial, technical, or marketing resources, resulting in intense competition in both markets. The company differentiates itself through its integrated approach combining population-based digital screening with targeted diagnostic confirmation and follow-up care, particularly via the synergy between its QHSLab platform and AllergiEnd® service line.

QHSLab, Inc. serves independent, physician-led primary care practices, generally consisting of one to ten providers, that control their own clinical workflows, bill Medicare and/or commercial insurance, manage diverse patient populations, and face operational and time constraints related to screening and follow-up care. The company does not focus its sales efforts on large health systems or hospital-owned practices. Specific customer names are not disclosed in the filing.